Head-to-head evidence
foslevodopa/foscarbidopa vs ND0612
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
foslevodopa/foscarbidopa · Vyalev
Marketed by AbbVie
NCT04380142 · Phase 3 · completed
The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).
ND0612
Developed by NeuroDerm Ltd.
NCT02577523 · Phase 2 · completed
Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · ND0612's landscape